Wisp vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wisp is a telehealth platform for women's sexual and reproductive health providing online consultations and medication delivery for birth control, UTIs, and sexual wellness.
About
Wisp is a women's health telehealth company founded in 2018 that provides convenient online care for sexual and reproductive health conditions including birth control, UTIs, STI treatment, yeast infections, bacterial vaginosis, and sexual wellness. The platform allows patients to consult with licensed providers online and receive prescription medications delivered by mail within 24 to 48 hours without requiring an in-person visit. Wisp operates in all 50 US states and has served over a million patients through its digital-first model. The company raised $25M and targets working women who want convenient access to reproductive health care without taking time off for in-person appointments. Wisp differentiates from general telehealth platforms by specializing exclusively in women's sexual and reproductive health, with clinical protocols and provider training optimized for the conditions most frequently experienced by women. The company offers both one-time treatment consultations and subscription plans for ongoing contraception management. Wisp has built a strong consumer brand through social media and content marketing focused on normalizing conversations about women's sexual health.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.